Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Lexaria Bioscience Corp. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −4 vs. Q3 2025
- Shares held
- 1.70M
- −16.1K (−0.9%) vs. Q3 2025
- Total value
- $1.05M
- −$581.6K (−35.6%) vs. Q3 2025
- New holders
- 2
- 7 more added
- Sold out
- 6
- 2 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LEXX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $920.0K |
| Q1 2026 | 28 | $1.17M |
| Q4 2025 | 21 | $1.05M |
| Q3 2025 | 25 | $1.63M |
| Q2 2025 | 21 | $2.00M |
| Q1 2025 | 22 | $2.12M |
| Q4 2024 | 25 | $3.03M |
| Q3 2024 | 27 | $3.25M |
| Q2 2024 | 28 | $5.72M |
| Q1 2024 | 25 | $3.23M |
| Q4 2023 | 20 | $1.49M |
| Q3 2023 | 15 | $1.77M |
| Q2 2023 | 14 | $651.4K |
| Q1 2023 | 17 | $1.85M |
| Q4 2022 | 16 | $1.71M |
| Q3 2022 | 16 | $1.68M |
| Q2 2022 | 16 | $1.67M |
| Q1 2022 | 12 | $1.41M |
| Q4 2021 | 13 | $1.85M |
| Q3 2021 | 11 | $2.83M |
| Q2 2021 | 10 | $2.93M |
| Q1 2021 | 9 | $1.78M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Lexaria Bioscience Corp.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Invenomic Capital Management LP | 470,915 | $290.6K | 0.01% | −6,286−1.3% | Reduced |
| UBS Group AG | 361,300 | $222.9K | 0.00% | +354,210+4,995.9% | Added |
| Vanguard Group Inc | 258,816 | $159.7K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 219,718 | $135.6K | 0.00% | +44,939+25.7% | Added |
| Toronto Dominion Bank | 140,013 | $86.5K | 0.00% | 00.0% | Unchanged |
| Byrne Asset Management LLC | 105,500 | $65.1K | 0.04% | +74,180+236.8% | Added |
| State Street Corp | 39,301 | $24.2K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 27,445 | $16.9K | 0.00% | 00.0% | Unchanged |
| Krilogy Financial LLC | 19,653 | $16.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 18,389 | $11.3K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 15,600 | $9.63K | 0.00% | +5,500+54.5% | Added |
| Bank of Montreal | 14,083 | $8.69K | 0.00% | +50+0.4% | Added |
| Royal Bank of Canada | 7,283 | $4.00K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 2,195 | $1.36K | 0.00% | +5+0.2% | Added |
| Federation des caisses Desjardins du Quebec | 382 | $233 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 203 | $126 | 0.00% | +30+17.3% | Added |
| MAI Capital Management | 200 | $124 | 0.00% | +200 | New |
| Farther Finance Advisors, LLC | 166 | $102 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 32 | $20 | 0.00% | −3,590−99.1% | Reduced |
| Gables Capital Management Inc. | 13 | $8 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 3 | $2 | 0.00% | +3 | New |
| Murchinson Ltd. | 0 | $0 | 0.00% | −419,590−100.0% | Sold out |
| Wealth Enhancement Advisory Services, LLC | 0 | $0 | 0.00% | −35,776−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −29,360−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −429−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −6−100.0% | Sold out |